Oncology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 1–12 of 239 articles
Quick answer
NovaPharmaNews Oncology hub for FDA covers 239 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Accord Launches OSVYRTI and JUBEREQ Biosimilars
FDA Accepts Daraxonrasib NDA for Pancreatic Cancer
FDA Approves GSK Jideytro for ROS1+ NSCLC
Study China outpaces the US in cancer approvals
FDA Approves New Breast Cancer Drug Revtorpyk
Summit Therapeutics Refocuses on Oncology Drug
AACR/ASCO Methods in Clinical 2026 Preview
FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
SLS stock: SELLAS REGAL nears final analysis
Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts
Tillomed Laboratories update: pipeline, melphalan and next catalysts
Breast Cancer Statistics Worldwide: What the Data Shows
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.